Skip Content
You are currently on the new version of our website. Access the old version .
  • Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 27, Issue 6

2020 December - 23 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (23)

  • Article
  • Open Access
9 Citations
1,589 Views
7 Pages

A Population-Based Study of Pulmonary Monitoring and Toxicity for Patients with Testicular Cancer Treated with Bleomycin

  • M.J. Raphael,
  • M.D. Lougheed,
  • X. Wei,
  • S. Karim,
  • A.G. Robinson,
  • P.L. Bedard and
  • C.M. Booth

1 December 2020

Background:Bleomycin is commonly used to treat advanced testicular cancer and can be associated with severe pulmonary toxicity. The primary objective of the present study was to describe the use of pulmonary function tests (PFTs) and chest imaging be...

  • Article
  • Open Access
8 Citations
2,480 Views
6 Pages

A Systematic Review and Network Meta-Analysis of Second-Line Therapy in Hepatocellular Carcinoma

  • S. Delos Santos,
  • S. Udayakumar,
  • A. Nguyen,
  • Y.J. Ko,
  • S. Berry,
  • M. Doherty and
  • K.K.W. Chan

1 December 2020

Background: In patients with advanced hepatocellular carcinoma (HCC) following sorafenib failure, it is unclear which treatment is most efficacious, as treatments in the second-line setting have not been directly compared and no standard therapy exis...

  • Article
  • Open Access
14 Citations
1,621 Views
6 Pages

The Cost of Failed First-Line Cancer Treatment Related to Continued Smoking in Canada

  • N. Iragorri,
  • B. Essue,
  • C. Timmings,
  • D. Keen,
  • H. Bryant and
  • G.W. Warren

1 December 2020

Background: Smoking by cancer patients and survivors causes adverse cancer treatment outcomes, but little information is available about how smoking can affect cancer treatment costs. Methods: We developed a model to estimate attributable cancer trea...

  • Article
  • Open Access
10 Citations
1,716 Views
8 Pages

Perspectives of Hematology Oncology Clinicians about Integrating Palliative Care in Oncology

  • R. Booker,
  • S. Dunn,
  • M.A. Earp,
  • A. Sinnarajah,
  • P.D. Biondo and
  • J.E. Simon

1 December 2020

Patients with hematologic malignancies receive palliative care (PC) less frequently and later than patients with solid tumours. We compared survey responses of hematology oncology clinicians with other oncology clinicians to better understand their c...

  • Article
  • Open Access
30 Citations
3,146 Views
9 Pages

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer

  • P.K. Cheema,
  • M. Gomes,
  • S. Banerji,
  • P. Joubert,
  • N.B. Leighl,
  • B. Melosky,
  • B.S. Sheffield,
  • T. Stockley and
  • D.N. Ionescu

1 December 2020

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including EGFR. EGFR mutation...

  • Case Report
  • Open Access
19 Citations
2,528 Views
6 Pages

1 December 2020

Introduction: The abscopal effect is a rarely observed outcome of radiotherapy wherein there is a reduction in metastatic disease burden outside of the targeted treatment area. Likely due to an in situ vaccine effect of radiotherapy, the abscopal eff...

  • Article
  • Open Access
24 Citations
3,778 Views
5 Pages

1 December 2020

Lymphedema is a chronic inflammatory condition that results from damage to the lymphatic system. Lymphedema is classified as either primary or secondary, the former being caused by a malformation of lymph vessels or nodes, and the latter resulting fr...

  • Article
  • Open Access
11 Citations
1,607 Views
10 Pages

1 December 2020

Background: Gastric adenosquamous carcinoma (GASC) is a rare entity with distinctive characteristics that are not fully understood. In the present study, we evaluated the characteristics of this rare disease. Methods: The U.S. Surveillance, Epidemiol...

  • Article
  • Open Access
13 Citations
1,810 Views
10 Pages

1 December 2020

Background: Treatment of hepatic metastases from neuroendocrine tumours improves survival and symptom relief. Hepatic arterial embolotherapy techniques include transarterial chemoembolization (TACE) and bland embolization (TAE). The relative efficacy...

  • Article
  • Open Access
2 Citations
1,466 Views
5 Pages

Presenting Stage and Risk Group in Men Dying of Prostate Cancer

  • S. Parimi,
  • S. Bondy,
  • M. Aparicio,
  • K. Sunderland,
  • J. Cho,
  • F. Bachand,
  • K. Nguyen Chi,
  • T. Pickles and
  • S. Tyldesley

1 December 2020

Introduction: Prostate cancer remains the 3rd leading cause of cancer-related mortality in Canadian men, and yet screening for prostate cancer continues to be controversial because the majority of men diagnosed with prostate cancer do not die of the...

  • Article
  • Open Access
8 Citations
2,037 Views
8 Pages

Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment

  • B.C. Tse,
  • B.I. Said,
  • Z.J. Fan,
  • K. Hueniken,
  • D. Patel,
  • G. Gill,
  • M. Liang,
  • M. Razooqi,
  • M.C. Brown and
  • G. O’Kane
  • + 7 authors

1 December 2020

Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with ALK-rearranged (ALK+) non-small-cell lung cancer (NSCLC). Clinical trial data can generally compare drugs in a pair-wise fashion. Real-world collec...

  • Article
  • Open Access
2 Citations
1,264 Views
9 Pages

Lysine Analogue Use during Cancer Surgery: A Survey from a Canadian Tertiary Care Centre

  • J. Montroy,
  • B. Hutton,
  • D.A. Fergusson,
  • A. Tinmouth,
  • L.T. Lavallée,
  • I. Cagiannos,
  • C. Morash,
  • A. Flaman and
  • R.H. Breau

1 December 2020

Background: When used during surgery, antifibrinolytic hemostatic agents such as lysine analogues are effective at reducing blood loss and the need for transfusions. Despite proven efficacy, use of hemostatic agents remains low during some surgeries....

  • Article
  • Open Access
24 Citations
2,585 Views
9 Pages

Comprehensive Genomic Profiling for Non-Small-Cell Lung Cancer: Health and Budget Impact

  • K. M. Johnston,
  • B. S. Sheffield,
  • S. Yip,
  • P. Lakzadeh,
  • C. Qian and
  • J. Nam

1 December 2020

Background: Single-gene tests and hotspot panels targeting specific subsets of biomarkers constitute the Canadian genomic testing landscape for non-small-cell lung cancer (nsclc). However, newer testing options such as comprehensive genomic profiling...

  • Article
  • Open Access
10 Citations
2,200 Views
12 Pages

1 December 2020

Background: In the katherine trial, adjuvant trastuzumab emtansine [T-DM1, Kadcyla (Genentech, South San Francisco, CA, U.S.A.)], compared with trastuzumab, significantly reduced the risk of recurrence or death by 50% (unstratified hazard ratio: 0.50...

  • Article
  • Open Access
2 Citations
2,553 Views
6 Pages

1 December 2020

Background: Primary care–led follow-up is a safe and acceptable alternative to oncologist-led follow-up. We sought to investigate patterns of primary care use during cancer follow-up care. Methods: We identified all persons in Nova Scotia, diagnosed...

  • Article
  • Open Access
4 Citations
2,257 Views
11 Pages

Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes

  • J. Tay,
  • S. Beattie,
  • C. Bredeson,
  • R. Brazauskas,
  • N. He,
  • I. A. Ahmed,
  • M. Aljurf,
  • M. Askar,
  • Y. Atsuta and
  • W. Saber
  • + 42 authors

1 December 2020

Background: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. Methods: We identified patients 40 years of age and older within the Center for International Blood and Marr...

  • Article
  • Open Access
7 Citations
1,494 Views
7 Pages

Code Status Communication Training in Postgraduate Oncology Programs: A Needs Assessment

  • O. H. Levine,
  • S. K. Dhesy-Thind,
  • M. M. McConnell,
  • M. C. Brouwers and
  • S. D. Mukherjee

1 December 2020

Background: Discussions with patients with cancer about cardiopulmonary resuscitation directives (code status) are often led by residents. This study was carried out in Canada to identify current educational practices and gaps in training for this co...

  • Article
  • Open Access
5 Citations
1,513 Views
7 Pages

1 December 2020

Background: Postgraduate medical education is undergoing a paradigm shift in many universities worldwide, transitioning from a time-based model to competency-based medical education (CBME). Residency programs might have to alter clinical rotations, e...

  • Article
  • Open Access
11 Citations
2,027 Views
11 Pages

Canadian Guidelines on the Management of Colorectal Peritoneal Metastases

  • A. Brind’Amour,
  • P. Dubé,
  • J.F. Tremblay,
  • M.L. Soucisse,
  • L. Mack,
  • A. Bouchard-Fortier,
  • J.A. McCart,
  • A. Govindarajan,
  • D. Bischof and
  • Lucas Sidéris
  • + 6 authors

1 December 2020

Modern management of colorectal cancer (CRC) with peritoneal metastasis (PM) is based on a combination of cytoreductive surgery (CRS), systemic chemotherapy, and hyperthermic intraperitoneal chemotherapy (HIPEC). Although the role of hipec has recent...

  • Article
  • Open Access
2 Citations
1,831 Views
13 Pages

First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma

  • S. Bhella,
  • Norma P. Varela,
  • A. Aw,
  • C. Bredeson,
  • M. Cheung,
  • M. Crump,
  • G. Fraser,
  • S. Sajkowski and
  • T. Kouroukis

1 December 2020

Background: In Ontario, no clearly defined standard of care for the management of mantle cell lymphoma (mcl) has been developed, and substantial variability from centre to centre is evident. This guidance document was prompted by the need to harmoniz...

  • Review
  • Open Access
9 Citations
2,032 Views
11 Pages

Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia

  • Versha Banerji,
  • A. Aw,
  • S. Robinson,
  • S. Doucette,
  • A. Christofides and
  • L.H. Sehn

1 December 2020

Chronic lymphocytic leukemia (cll) is the most commonly diagnosed adult leukemia in Canada. Biologic heterogeneity of cll between patients results in variable disease trajectories and responses to therapy. Notably, compared with patients lacking high...

  • Review
  • Open Access
13 Citations
2,259 Views
8 Pages

1 December 2020

Background: We conducted this meta-analysis and systematic literature review to study the ability of PD-L1 to predict objective response in patients with urothelial cancer treated with PD-1/PD-L1 inhibitors. Methods: Relevant studies of PD-1 or PD-L1...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729